T315I is the most common mutation in TKI-resistant CML1-3

Explore T315I mutation in chronic phase chronic myeloid leukemia

Among patients with a BCR::ABL1 mutation,
the frequency of the T315I mutation was 10-27%.2,4-6

Reviews of the clinical literature showed that:

Development of the T315I mutation leads to resistance with 1st- or 2nd-generation TKIs1,7

BCR::ABL1 mutation testing helps inform TKI treatment choice7,8

ICLUSIG is the only 3rd-generation pan-mutational TKI that delivers proven long-term efficacy for patients with a T315I mutation9-11

NCCN category 2A treatment option.

NCCN Category 2A treatment option in CML based on BCR::ABL1 mutation status7

  • Potatinib is a preferred subsequent therapy option for patients with no identifiable BCR::ABL1 mutations:
    • Ponatinib is a treatment option for CP-CML with resistance or intolerance to at-least 2 prior TKIs or for patients with AP-CML or BP-CML for whom no other TKI is indicated
    • Ponatinib is preferred for patients with AP-CML or 
BP-CML with a T315I mutation and is a treatment option for patients with this mutation in CP-CML
70%.

70% of CP-CML patients with a T315I mutation in the PACE trial (n=64) achieved MCyR, and responses were deep and durable11

PACE trial design

PACE was a single-arm, open-label, international, multicenter, phase 2 trial in adult patients with CML or Ph+ ALL whose disease was considered to be resistant or intolerant to a prior kinase inhibitor or who had T315I mutation (N=449; n=64 T315I-positive CML). At study completion, the median duration of follow-up for the trial (all cohorts) was 40.5 months (range 0.1 months to 79.5 months). The major efficacy outcome measure (primary endpoint) for patients with CP-CML was MCyR by 12 months, which included CCyR and PCyR.10,11

ICLUSIG 5-year safety profile in CP-CML

ICLUSIG simple once-daily
oral dosing

AP-CML=accelerated-phase chronic myeloid leukemia; BP-CML=blast-phase chronic myeloid leukemia; CCyR=complete cytogenetic response; CML=chronic myeloid leukemia; CP‑CML=chronic phase chronic myeloid leukemia; MCyR=major cytogenetic response; NCCN=National Comprehensive Cancer Network® (NCCN®); PCyR= partial cytogenetic response; Ph+ ALL=Philadelphia chromosome-positive acute lymphoblastic leukemia; TKI=tyrosine kinase inhibitor.

CML Patient Profiles

""

CML resources and support

""